XML 59 R44.htm IDEA: XBRL DOCUMENT v3.26.1
Equity-Based Compensation (Tables)
 12 Months Ended
Jun. 30, 2026
Share-Based Payment Arrangement [Abstract]  
Schedule of Restricted Stock Units and Target Performance Stock Units Granted to be Settled in Stock
The following table summarizes the activity related to RSUs and target PSUs granted to the Company’s employees to be settled in stock (RSUs and PSUs in thousands):
Fiscal 2026
Fiscal 2025
Fiscal 2024
Number
of
shares
Weighted
average
grant-
date fair
value
Number
of
shares
Weighted
average
grant-
date fair
value
Number
of
shares
Weighted
average
grant-
date fair
value
RSUs and PSUs
Unvested units at beginning of the year4,940 $36.75 4,801 $35.20 4,284 $33.72 
Granted1,523 45.90 1,945 37.58 3,209 35.13 
Vested(2,325)36.84 (1,685)34.68 (2,153)31.97 
Cancelled(80)43.23 (121)39.57 (539)35.28 
Unvested units at the end of the year(a)
4,058 $42.48 4,940 $36.75 4,801 $35.20 
(a)
The intrinsic value of unvested RSUs and target PSUs as of June 30, 2026 was approximately $170 million.
Schedule of Stock Options and PSOs Granted under SAP
The following table summarizes information about the Company’s stock options and PSOs granted under the SAP during fiscal 2026, 2025 and 2024 (options in thousands):
Fiscal 2026
Fiscal 2025
Fiscal 2024
Number of options Weighted average exercise priceNumber of options Weighted average exercise priceNumber of options Weighted average exercise price
Outstanding at the beginning of the year16,277 $35.14 18,326 $33.75 17,048 $33.12 
Granted2,380 54.06 3,386 38.98 3,927 34.77 
Exercised(a)
(4,341)36.01 (5,243)32.67 (1,216)27.85 
Cancelled(215)39.59 (192)37.77 (1,433)34.30 
Outstanding at the end of the year(b)
14,101 $37.99 16,277 $35.14 18,326 $33.75 
Exercisable at the end of the year(c)
4,954 $31.99 5,907 $34.08 8,158 $32.95 
Weighted average grant-date fair value of options granted$18.05 $11.67 $10.30 
Weighted average remaining contractual term of options outstanding at the end of the year6.90 years6.35 years5.97 years
Weighted average remaining contractual term of options exercisable at the end of the year4.98 years3.51 years3.51 years
(a)
During fiscal 2026, 2025 and 2024, the Company received approximately $156 million, $171 million and $34 million, respectively, in cash payments from the exercise of options.
(b)
The intrinsic value of options outstanding as of June 30, 2026, 2025 and 2024 was $204.2 million, $340.2 million and $31.7 million, respectively.
(c)
The intrinsic value of options exercisable as of June 30, 2026, 2025 and 2024 was $99.9 million, $129.7 million and $28.7 million, respectively.
Schedule of Weighted Average Assumptions Used for Estimated Fair Value of Stock Option Grant
The fair value of each PSO grant is estimated on the date of grant with the following weighted average assumptions used for grants during fiscal 2026, 2025 and 2024:
For the years ended June 30,
202620252024
Expected volatility32.19 %30.17 %31.63 %
Risk-free interest rate4.23 %3.86 %3.96 %
Expected dividend yield1.00 %1.39 %1.44 %
Expected term6.50 years7.15 years6.50 years
Schedule of Equity-Based Compensation
The following table summarizes the Company’s equity-based compensation:
For the years ended June 30,
202620252024
(in millions)
Equity-based compensation
$132 $135 $90 
Intrinsic value of all settled equity-based awards$245 $134 $78 
Tax benefit on settled equity-based awards$37 $24 $12